Relacorilant is named as a drug or biological intervention in 2 clinical trials in our USA and UK trial registers, 1 of which is recruiting. The lead sponsor is Corcept Therapeutics. Registered phases: Phase 3 and Phase 2. Conditions studied include Peritoneal Neoplasms; Ovarian Neoplasm; Fallopian Tube Neoplasms.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms |
Phase 2 | Recruiting |
| NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ClinicalTrials.gov ↗) Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Peritoneal Neoplasms | 2 |
| Ovarian Neoplasm | 1 |
| Fallopian Tube Neoplasms | 1 |
| Ovarian Cancer | 1 |
| Fallopian Tube Cancer | 1 |
| Endometrial Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Corcept Therapeutics | 2 |
| Register | Relacorilant trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Relacorilant works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Relacorilant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.